217 results on '"Osman, Keren"'
Search Results
2. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
3. Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy – Are We over-Treating with Anti-Microbials?
4. CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
5. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter
6. Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD
7. CAR T cell Therapy for Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplantation: A Safe and Feasible Therapy for An Orphan Disease
8. Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation
9. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19
10. A Refined Approach to Onboarding CAR-T and Cellular Therapy Products: A Learned Experience
11. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
12. Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis
13. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019
14. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19.
15. Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
16. Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
17. Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis
18. Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)
19. CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma
20. Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)
21. Abstract LB027: Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147)
22. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization
23. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis
24. Retrospective analysis of prognosticators in patients with relapsed Hodgkin’s Lymphoma treated with autologous transplant: results of a single center
25. Clinical Program Manager and Nurse Practitioner Specializing in Immune Effector Cell Therapy
26. 184: Mesenchymal Stromal Cell Therapy for Acute Respiratory Distress Syndrome due to COVID-19
27. The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns
28. 801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients
29. Oncologic Emergencies
30. Combination strategies to enhance antitumor ADCC
31. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma
32. A phase I/II study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis.
33. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
34. Cytopenias Following CAR-T Cell Therapy - a Single Center Experience
35. A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis
36. Autologous Stem Cell Transplantation for Plasma Cell Disorders
37. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma
38. A case report of secondary autograft failure due to Gaucher disease
39. Stem Cell Transplantation
40. 253 - Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
41. 234 - Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
42. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
43. Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma
44. Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma.
45. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis
46. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden
47. 115 - Clinical Program Manager and Nurse Practitioner Specializing in Immune Effector Cell Therapy
48. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
49. A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
50. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.